In conclusion, overlapping yet distinct pharmacological properties of ranibizumab and bevacizumab indicate that safety or efficacy data from one cannot be extrapolated to the other. and properties and preclinical safety data. Materials and methods This review was based on a literature search performed in http://PubMed.gov using two separate searches. cell functioning. Compared with bevacizumab, ranibizumab […]